Logo image of ALNOX.PA

NOXXON PHARMA NV (ALNOX.PA) Stock Fundamental Analysis

EPA:ALNOX - Euronext Paris - Matif - NL0012044762 - Common Stock - Currency: EUR

0.041  -0.01 (-18%)

Fundamental Rating

2

ALNOX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. While ALNOX seems to be doing ok healthwise, there are quite some concerns on its profitability. ALNOX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALNOX had negative earnings in the past year.
ALNOX.PA Yearly Net Income VS EBIT VS OCF VS FCFALNOX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -5M -10M -15M

1.2 Ratios

Industry RankSector Rank
ROA -147.9%
ROE N/A
ROIC -219.68%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALNOX.PA Yearly ROA, ROE, ROICALNOX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALNOX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALNOX.PA Yearly Profit, Operating, Gross MarginsALNOX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -10K -20K -30K

More info and screens

5

2. Health

2.1 Basic Checks

ALNOX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ALNOX has more shares outstanding
Compared to 1 year ago, ALNOX has an improved debt to assets ratio.
ALNOX.PA Yearly Shares OutstandingALNOX.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M
ALNOX.PA Yearly Total Debt VS Total AssetsALNOX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M

2.2 Solvency

ALNOX has an Altman-Z score of -28.39. This is a bad value and indicates that ALNOX is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for ALNOX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.39
ROIC/WACC-29.25
WACC7.51%
ALNOX.PA Yearly LT Debt VS Equity VS FCFALNOX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 1.84 indicates that ALNOX should not have too much problems paying its short term obligations.
A Quick Ratio of 1.84 indicates that ALNOX should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.84
ALNOX.PA Yearly Current Assets VS Current LiabilitesALNOX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

ALNOX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.04%, which is quite impressive.
EPS 1Y (TTM)40.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.06% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.23%
EPS Next 2Y28.6%
EPS Next 3Y16.4%
EPS Next 5Y10.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALNOX.PA Yearly Revenue VS EstimatesALNOX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2022 1M 2M 3M 4M 5M
ALNOX.PA Yearly EPS VS EstimatesALNOX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALNOX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALNOX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALNOX.PA Price Earnings VS Forward Price EarningsALNOX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.48
ALNOX.PA Per share dataALNOX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

A more expensive valuation may be justified as ALNOX's earnings are expected to grow with 16.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.6%
EPS Next 3Y16.4%

More info and screens

0

5. Dividend

5.1 Amount

ALNOX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOXXON PHARMA NV

EPA:ALNOX (7/18/2022, 7:00:00 PM)

0.041

-0.01 (-18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.05M
Analysts84
Price Target7.39 (17924.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB N/A
EV/EBITDA 0.48
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.06
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -147.9%
ROE N/A
ROCE N/A
ROIC -219.68%
ROICexc N/A
ROICexgc -219.88%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.84
Altman-Z -28.39
F-Score3
WACC7.51%
ROIC/WACC-29.25
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.23%
EPS Next Y-19.23%
EPS Next 2Y28.6%
EPS Next 3Y16.4%
EPS Next 5Y10.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A